Throughout the last three months, 11 analysts have evaluated Celldex Therapeutics CLDX, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 5 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.64, with a high estimate of $80.00 and a low estimate of $37.00. Experiencing a 2.06% decline, the current average is now lower than the previous average price target of $66.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Celldex Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
| David Lebowitz | Citigroup | Announces | Buy | $70.00 | - |
| Richard Law | Goldman Sachs | Announces | Neutral | $45.00 | - |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
| Andy Chen | Wolfe Research | Maintains | Outperform | $51.00 | $51.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Derek Archila | Wells Fargo | Raises | Equal-Weight | $37.00 | $35.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Celldex Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celldex Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Celldex Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Celldex Therapeutics Better
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
A Deep Dive into Celldex Therapeutics's Financials
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Celldex Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 832.09%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -1434.83%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -4.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.18%, the company showcases efficient use of assets and strong financial health.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
